The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Acute liver failure following atorvastatin dose escalation: Is there a threshold dose for idiosyncratic hepatotoxicity?
Abstract
The bulk of hepatotoxicity (drug induced liver injury, DILI) cases in clinical practice is idiosyncratic in nature. This assumption is based on the apparent absence of dose dependency and the unpredictability of the reaction, which presents after a relatively long latency period of drug exposure in susceptible individuals. Recent evidence suggests that the administration of high oral daily dose of drugs that undergo extensive hepatic metabolism does influence the risk of developing idiosyncratic DILI (IDILI) [1,2].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In some instances, dose escalation may also increase the risk of developing idiosyncratic DILI as seen with azathioprine, whereas dose reduction or increasing the dosing interval may improve tolerability.35–37”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Björnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Research works printed but not linked: 8
- Lammert, 2008, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals, Hepatology, 47, 2003, 10.1002/hep.22272 · DOI · Paper page
- Lammert, 2010, Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events, Hepatology, 51, 615, 10.1002/hep.23317 · DOI · Paper page
- Malhotra, 2001, Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia, Drugs, 61, 1835, 10.2165/00003495-200161120-00012 · DOI
- Björnsson, 2012, Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing, J Hepatol, 56, 374, 10.1016/j.jhep.2011.07.023 · DOI · Paper page
- Bader, 2010, Liver tests are irrelevant when prescribing statins, Lancet, 376, 1882, 10.1016/S0140-6736(10)62142-3 · DOI
- Russo, 2014, Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network, Hepatology, 60, 679, 10.1002/hep.27157 · DOI · Paper page
- Perdices, 2014, Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry, Rev Esp Enferm Dig, 106, 246
- Chen, 2013, High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury, Hepatology, 58, 388, 10.1002/hep.26208 · DOI · Paper page
Cited by
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Self-citationEASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure
Wendon, J., Cordoba, J., Dhawan, A., Larsen, F. S., Manns, M., Nevens, F., Samuel, D., Simpson, K. J., Yaron, I., & Bernardi, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.003 · Cited by 917
Drug-induced liver injury: Interactions between drug properties and host factors
Chen, M., Suzuki, A., Borlak, J., Andrade, R. J., & Lucena, M. I. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.016 · Cited by 405
Self-citationAASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Drug induced liver injury: an update
Garcia-Cortes, M., Robles-Diaz, M., Stephens, C., Ortega-Alonso, A., Lucena, M. I., & Andrade, R. J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02885-1 · Cited by 286
Self-citation
Metadata
- Authors
- Carrascosa, M. F., Salcines-Caviedes, J. R., Lucena, M. I., & Andrade, R. J.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 62
- Issue
- 3
- Pages
- 751-752
- ISSN
- 0168-8278
- Cited by
- 34
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.